comprehensive -WSS

comprehensive

author：comprehensive 2025-10-01 00:58:15 - browse：89

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Why did Pfizer dish out millions for a Super Bowl ad?

entertainment

WSS

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Police still searching for prisoner who escaped from NYC hospital

Why failed clinical trials don’t always spell doom for a new drug

Private equity deals in Medicare Advantage declines

What should King Charles tell the public about his cancer?

'Revelatory' study finds a smoking impact that remains after quitting

Wikipedia

comprehensive

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

American woman, child freed after being kidnapped in Haiti last month

Virginia high school admissions case could be legal follow

Maui's cultural, historic landmarks damaged in the devastating wildfires

Jerome Adams on the need for new antivirals for Covid

Friends ask where James Watson's attitudes about race came from

Psychedelics group wrestles with new pharma identity

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

Continuity nursing helped my family in our darkest PICU moments

The Readout: Gilead, Bernie Sanders, and other pharma news

leisure time

To avoid data mishandling cases, universities eye AI and other tools

Gilead might be held responsible for not developing a drug

The dental labor crisis is a moment of opportunity

Methadone doses haven’t kept up in the age of fentanyl

Man killed during FBI raid in connection with threats against Biden, other officials

Naloxone nonprofit donates 200,000 doses after FDA approval

focus

entertainment

entertainment

leisure time